Syros Pharmaceuticals (NASDAQ:SYRS) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Syros Pharmaceuticals (NASDAQ:SYRS) in a report released on Saturday. The firm issued a sell rating on the stock.

Syros Pharmaceuticals Trading Down 7.3 %

Shares of SYRS stock opened at $0.03 on Friday. Syros Pharmaceuticals has a 1 year low of $0.02 and a 1 year high of $6.93. The firm has a market capitalization of $745,929.60, a P/E ratio of -0.01 and a beta of 1.31. The firm’s fifty day moving average price is $0.14 and its two-hundred day moving average price is $0.78.

Hedge Funds Weigh In On Syros Pharmaceuticals

An institutional investor recently bought a new position in Syros Pharmaceuticals stock. Two Sigma Securities LLC bought a new position in shares of Syros Pharmaceuticals, Inc. (NASDAQ:SYRS) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 107,742 shares of the company’s stock, valued at approximately $25,000. Two Sigma Securities LLC owned about 0.40% of Syros Pharmaceuticals as of its most recent SEC filing. 91.47% of the stock is owned by institutional investors and hedge funds.

Syros Pharmaceuticals Company Profile

Syros Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development of treatment for hematologic malignancies. The company's lead product candidates are Tamibarotene, a selective retinoic acid receptor alpha agonist, which is in Phase III clinical trial for genomically defined subset of patients with myelodysplastic syndrome and Phase II clinical trial for patients with acute myeloid leukemia; SY-2101, a novel oral form of arsenic trioxide for treating patients with acute promyelocytic leukemia; and SY-5609, a cyclin-dependent kinase 7 inhibitor, which is in a Phase I clinical trial in patients with select advanced solid tumors.